Absolute risk differences indicated larger reductions in anxiety disorders among individuals with type 2 diabetes than among those without diabetes when tirzepatide or semaglutide was compared with naltrexone-bupropion
10.21037/jtd-2025-1159 J Thorac Dis
USA 114 , 37563761 (2017)
Periodic reassessment every 6 to 12 weeks by labs and outcome measures enables clinicians to fine-tune the protocol
Naveed Sattar, a professor of metabolic medicine at the University of Glasgow, said the weight-loss drugs are promising
Tissue Eng B Rev 17:165176 Lovric-Bencic M, Sikiric P, Hanzevacki JS, Seiwerth S, Rogic D, Kusec V, Aralica G, Konjevoda P, Batelja L, Blagaic AB (2004) Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse